Page 12 - IMO-2-2

Innovative Medicines & Omics Pharmacotherapy of obesity

to cognitive methods in an effort to address factors of the patient to attain major weight loss, but it does require
influence in weight loss and long-term maintenance. sensitive counseling and also well-oriented medical team
This approach includes self-monitoring, goal setting, participation, including psychologists, dietetics, and
problem-solving, and preventing relapse – specifically specialized healthcare professionals. The patients should
adapted to the needs of the patient. Weight loss effect be informed about the potential complications and realistic
of this approach is considerable, evidenced by patients expectations of success. 51
reporting achievement of as much as 15% body weight
reduction after 12 months, suggesting that this therapy 11. Pharmacotherapy of obesity
may prove to be more effective than traditional weight- The criteria for an obese patient to start medication include
loss programs. 47 low motivation and commitment, uncontrolled BMI, and
failed lifestyle modifications. The early treatment along
52
10.4. Lifestyle modifications with progressive behavior modification is one of the
Both sleep and stress are significant contributors to the most important steps. An obese individual may consider
reduction in obesity. For instance, poor sleep duration such starting medication when their BMI is 27 or higher with
as 5.5 h is associated with less fat loss and higher losses of at least one comorbidity, or when their BMI is 30 or
muscle mass compared to sufficient sleep, which is usually above. Medical treatments combined with behavioral
49
considered to be 8.5 h of sleep, besides having higher levels and psychological interventions may achieve appropriate
of hunger and changes in the way fat is metabolized in weight loss and enhancement of long-term success despite
the body. Sleep deficiency keeps the human body fueled previous difficulties in weight management. Table 1
53
with hunger, hence probably leading to overeating and reviews the approved medications for obesity management,
interference with losing weight. Furthermore, emotional recommended dosage, mechanism of action, possible side
48
stress linked to sleep disturbance may exacerbate obesity, effects, and contraindications, whereas Figure 1 shows
and thus underscore the need for major management in the timeline of the Food and Drug Administration (FDA)
the treatment of obesity. 49 approval of these drugs.
10.5. Support groups and counseling 11.1. Orlistat

Support systems for obesity can be strengthened by Orlistat is the saturated derivative of lipstatin, a potent
adopting global strategies, interdisciplinary collaboration, natural inhibitor of pancreatic lipases isolated from the
and systems such as mapping and modeling. Furthermore, bacterium Streptomyces toxytricini. However, due to its
the adoption of both traditional approaches and new relative simplicity and stability, orlistat was chosen over
methods, while bridging gaps of research and education lipstatin for development as an anti-obesity drug. Orlistat
with policy and action, should improve the prevention and prevents fat from being absorbed, hence decreasing the
control of obesity. Moreover, the establishment of support overall caloric intake. It has been documented to cause
49
groups that include patients, dietitians, personal trainers, significant reduction of body weight, visceral fat, and its
and psychologists helps patients stay more consistent and related disorders such as hypercholesterolemia, insulin
dedicated to their weight loss endeavor. resistance, and blood glucose levels in clinical tests. Recent
studies have also considered its use in cancer treatment.
10.6. Bariatric surgery Orlistat, in fact, has emerged to inhibit tumor growth
Bariatric surgery is a choice for those obese patients, where through interference with key cellular pathways, induction
other treatments have failed, generally in people with a of tumor cell death, and interference with the growth
BMI above 40 or those with a BMI above 35 with comorbid cycle. The involvement of orlistat in obesity and cancer
conditions. There are many different surgical techniques, underlines its other important therapeutic role beyond
spanning from laparoscopic to open procedures, weight management. As an inhibitor of gastrointestinal
54
all of which lead to greater weight loss compared to lipase, orlistat plays an important role by inhibiting
conservative management and improvement in obesity- enzymes in lipid metabolism, preventing triacylglycerol
related comorbid conditions. Surgery is indicated for from undergoing hydrolysis to fatty acids and nitro-
50

Figure 1. Timeline of FDA approval for obesity management drugs
Abbreviation: FDA: Food and Drug Administration.

Volume 2 Issue 2 (2025) 6 doi: 10.36922/imo.8316